Plus Therapeutics (NASDAQ:PSTV) Price Target Cut to $5.50 by Analysts at HC Wainwright

Plus Therapeutics (NASDAQ:PSTV) had its price objective reduced by analysts at HC Wainwright from $8.00 to $5.50 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 261.84% from the company’s previous close.

Other analysts have also issued research reports about the company. D. Boral Capital initiated coverage on Plus Therapeutics in a report on Monday, March 17th. They set a “buy” rating and a $9.00 target price on the stock. Ascendiant Capital Markets dropped their target price on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th.

Plus Therapeutics Trading Up 3.4 %

Shares of PSTV stock opened at $1.52 on Friday. The firm’s fifty day moving average price is $1.11 and its two-hundred day moving average price is $1.24. Plus Therapeutics has a 1 year low of $0.24 and a 1 year high of $2.67. The firm has a market capitalization of $8.96 million, a P/E ratio of -0.60 and a beta of 0.73.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.